Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Shuertong Dispersible Tablets** is an investigational oral traditional Chinese medicine formulation developed by Kunming Bondir Pharmaceutical Research for pain associated with the traditional Chinese medicine pattern of qi stagnation and blood stasis. A completed Chinese Phase 1 single-ascending-dose study in healthy volunteers evaluated safety and tolerability and was intended to inform a subsequent multiple-dose study. Public sources describe therapeutic functions as promoting blood circulation, resolving blood stasis, regulating qi and collaterals, cooling the blood, and relieving pain; however, the precise active composition and molecular mechanism have not been publicly identified. ([pharnexcloud.com](https://www.pharnexcloud.com/data/lcsy_f0feb92ccfc89fdcaec5db2136e6f672.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuertong Dispersible Tablets.